1. Home
  2. RYTM vs MTDR Comparison

RYTM vs MTDR Comparison

Compare RYTM & MTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • MTDR
  • Stock Information
  • Founded
  • RYTM 2008
  • MTDR 2003
  • Country
  • RYTM United States
  • MTDR United States
  • Employees
  • RYTM N/A
  • MTDR N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • MTDR Oil & Gas Production
  • Sector
  • RYTM Health Care
  • MTDR Energy
  • Exchange
  • RYTM Nasdaq
  • MTDR Nasdaq
  • Market Cap
  • RYTM 5.9B
  • MTDR 6.4B
  • IPO Year
  • RYTM 2017
  • MTDR 2012
  • Fundamental
  • Price
  • RYTM $97.61
  • MTDR $46.89
  • Analyst Decision
  • RYTM Strong Buy
  • MTDR Buy
  • Analyst Count
  • RYTM 13
  • MTDR 14
  • Target Price
  • RYTM $101.92
  • MTDR $68.86
  • AVG Volume (30 Days)
  • RYTM 578.8K
  • MTDR 1.9M
  • Earning Date
  • RYTM 08-05-2025
  • MTDR 07-22-2025
  • Dividend Yield
  • RYTM N/A
  • MTDR 2.66%
  • EPS Growth
  • RYTM N/A
  • MTDR N/A
  • EPS
  • RYTM N/A
  • MTDR 6.81
  • Revenue
  • RYTM $156,287,000.00
  • MTDR $3,504,171,000.00
  • Revenue This Year
  • RYTM $37.86
  • MTDR $17.85
  • Revenue Next Year
  • RYTM $72.72
  • MTDR $1.18
  • P/E Ratio
  • RYTM N/A
  • MTDR $6.89
  • Revenue Growth
  • RYTM 53.55
  • MTDR 16.16
  • 52 Week Low
  • RYTM $43.57
  • MTDR $35.19
  • 52 Week High
  • RYTM $99.04
  • MTDR $64.05
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 73.48
  • MTDR 41.76
  • Support Level
  • RYTM $95.30
  • MTDR $45.87
  • Resistance Level
  • RYTM $99.04
  • MTDR $48.00
  • Average True Range (ATR)
  • RYTM 3.21
  • MTDR 1.49
  • MACD
  • RYTM 0.20
  • MTDR -0.22
  • Stochastic Oscillator
  • RYTM 90.50
  • MTDR 15.43

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About MTDR Matador Resources Company

Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.

Share on Social Networks: